We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Clinical characteristics and outcomes of critically ill patients with acute COVID-19 with Epstein-Barr virus reactivation.
- Authors
Xie, Yun; Cao, Song; Dong, Hui; Lv, Hui; Teng, Xiaolei; Zhang, Jiaxiang; Wang, Tao; Zhang, Xiaoyan; Qin, Yun; Chai, Yujing; Yang, Luyu; Liu, Jun; Wang, Ruilan
- Abstract
<bold>Background: </bold>Our goal is to further elucidate the clinical condition and prognosis of patients with severe acute COVID-19 with EBV reactivation.<bold>Method: </bold>This is a retrospective single-center study of COVID-19 patients admitted to the intensive care unit of Wuhan No. 3 Hospital (January 31 to March 27, 2020). According to whether Epstein-Barr virus reactivation was detected, the patients were divided into an EBV group and a Non-EBV group. Baseline data were collected including epidemiological, larithmics, clinical and imaging characteristics, and laboratory examination data.<bold>Results: </bold>Of the 128 patients with COVID-19, 17 (13.3%) were infected with Epstein-Barr virus reactivation. In the symptoms,the rate of tachypnoea in the EBV group was apparently higher than that in the Non-EBV group. In lab tests, the lymphocyte and albumin of EBV group decreased more significantly than Non-EBV group, and the D-dimer and serum calcium of EBV group was higher than Non-EBV group. Regarding the infection index, CRP of EBV group was apparently above the Non-EBV group, and no significant difference was found in procalcitonin of the two groups. The incidence of respiratory failure, ARDS, and hypoproteinaemia of EBV group had more incidence than Non-EBV group. The 28-day and 14-day mortality rates of EBV group was significantly higher than that of Non-EBV group.<bold>Conclusions: </bold>In the COVID-19 patients, patients with EBV reactivation had higher 28-day and 14-day mortality rates and received more immuno-supportive treatment than patients of Non-EBV group.
- Subjects
COVID-19; VIRUS reactivation; EPSTEIN-Barr virus; TREATMENT effectiveness; CRITICALLY ill
- Publication
BMC Infectious Diseases, 2021, Vol 21, Issue 1, p1
- ISSN
1471-2334
- Publication type
journal article
- DOI
10.1186/s12879-021-06638-y